Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Decreased clearance of CNS beta-amyloid in Alzheimer's disease.

Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ.

Science. 2010 Dec 24;330(6012):1774. doi: 10.1126/science.1197623. Epub 2010 Dec 9.

2.

Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.

Lucey BP, Mawuenyega KG, Patterson BW, Elbert DL, Ovod V, Kasten T, Morris JC, Bateman RJ.

JAMA Neurol. 2017 Feb 1;74(2):207-215. doi: 10.1001/jamaneurol.2016.4202.

PMID:
27992627
3.

Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.

Miners JS, Clarke P, Love S.

Brain Pathol. 2017 May;27(3):305-313. doi: 10.1111/bpa.12392. Epub 2016 Jul 8.

PMID:
27248362
4.

Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics.

Mawuenyega KG, Kasten T, Sigurdson W, Bateman RJ.

Anal Biochem. 2013 Sep 1;440(1):56-62. doi: 10.1016/j.ab.2013.04.031. Epub 2013 May 25.

5.

Differential changes in Aβ42 and Aβ40 with age.

Miners JS, Jones R, Love S.

J Alzheimers Dis. 2014;40(3):727-35. doi: 10.3233/JAD-132339.

PMID:
24503618
6.

Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery.

Omtri RS, Davidson MW, Arumugam B, Poduslo JF, Kandimalla KK.

Mol Pharm. 2012 Jul 2;9(7):1887-97. doi: 10.1021/mp200530q. Epub 2012 Jun 1.

8.

The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.

Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L.

Neurosci Lett. 2007 Nov 12;427(3):127-31. Epub 2007 Sep 20.

PMID:
17936506
9.

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J.

Am J Pathol. 1999 Sep;155(3):853-62.

10.

Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM.

Neurobiol Aging. 2014 Feb;35(2):357-64. doi: 10.1016/j.neurobiolaging.2013.07.027. Epub 2013 Sep 4.

11.

Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.

Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H.

Neuromolecular Med. 2012 Mar;14(1):65-73. doi: 10.1007/s12017-012-8171-4. Epub 2012 Feb 18.

PMID:
22350541
12.

A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.

Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Höjrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J.

J Alzheimers Dis. 2013;33(4):1021-32. doi: 10.3233/JAD-2012-121471.

PMID:
23076076
13.

Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV.

J Cereb Blood Flow Metab. 2007 May;27(5):909-18. Epub 2006 Nov 1.

14.

Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system.

Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ.

PLoS One. 2014 Mar 19;9(3):e89998. doi: 10.1371/journal.pone.0089998. eCollection 2014.

15.

Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.

Luo X, Shi H, Hou L, Zhong X, Chen X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chen J, Fang Y, He H, Ning Y.

Eur J Neurol. 2015 May;22(5):853-8. doi: 10.1111/ene.12680. Epub 2015 Feb 23.

PMID:
25707998
16.

Conversion of Aβ43 to Aβ40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme.

Liu S, Liu J, Miura Y, Tanabe C, Maeda T, Terayama Y, Turner AJ, Zou K, Komano H.

J Neurosci Res. 2014 Sep;92(9):1178-86. doi: 10.1002/jnr.23404. Epub 2014 May 14.

PMID:
24823497
17.

Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers.

Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ.

Sci Transl Med. 2013 Jun 12;5(189):189ra77. doi: 10.1126/scitranslmed.3005615.

18.

Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils.

Gu L, Guo Z.

J Neurochem. 2013 Aug;126(3):305-11. doi: 10.1111/jnc.12202. Epub 2013 Mar 12.

19.

Dissociation of β-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β-amyloid-42 assembly.

Takamura A, Kawarabayashi T, Yokoseki T, Shibata M, Morishima-Kawashima M, Saito Y, Murayama S, Ihara Y, Abe K, Shoji M, Michikawa M, Matsubara E.

J Neurosci Res. 2011 Jun;89(6):815-21. doi: 10.1002/jnr.22615. Epub 2011 Mar 10.

PMID:
21394760
20.

Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.

Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R.

Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7. doi: 10.1073/pnas.0805902105. Epub 2008 Sep 8.

Supplemental Content

Support Center